Hyrimoz(Cf) Pen (Adalimumab-Adaz) Patent Expiration, LOE Window & CMS Spending

Hyrimoz(Cf) Pen (Adalimumab-Adaz) by Sandoz: Biologic BLA (Purple Book Regime), 0 AB generics, $13.3M 2024 CMS Part D & Medicaid spend, and $19,730 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSandoz
FDA Application & PathwayB761071 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$13.3M
2024 Medicare Part D Spend$7.9M
2024 Medicaid Spend$5.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($19,730 intro WAC)